Open an account

Mesoblast

MESO · ASX

$12.28−$0.27 (−2.15%)TodayMarket closed ·
Prev close $12.55

About MESO

Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. The company is headquartered in Melbourne, Victoria and currently employs 81 full-time employees. The company went IPO on 2004-12-16. The firm is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The firm has developing a range of late-stage product candidates, derived from its first and second generation proprietary mesenchymal lineage cell therapy technology platforms therapies for distinct indications. The Company’s Ryoncil (remestemcel-L-rknd) is an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy. Its other product candidate is Revascor (rexlemestrocel-L). Rexlemestrocel-L is second generation mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of: chronic heart failure (chf) and chronic low back pain (clbp) due to degenerative disc disease. The two products have been commercialized in Japan and Europe by the Company's licensees.

Employees
81
Headquarters
Melbourne, Victoria
Listed
Dec 16, 2004
Sector
Health Care
Industry
Biotechnology
Website
mesoblast.com

MESO key statistics

Market cap
2.38B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
284.48K
Volume
102.60K
Open price
$12.38
High today
$12.38
Low today
$12.21
52 Week high
$21.50
52 Week low
$11.89

Mesoblast (MESO) at a glance

As of Oct 23, 2026, Mesoblast (MESO) shares are priced at $12.28, giving the company a market cap of 2.38B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $12.21 and $12.38. The current price is 0.6% above the day's low and 0.8% below its high.

Volume so far is 102.60K shares, below the average of 284.48K shares a day.

Over the past year Mesoblast has ranged from $11.89 to $21.50, and now sits 4% of the way up that range.

Mesoblast met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q4 FY23 it reported -$0.0266 per share against an estimate of -$0.1252.

The average analyst price target is $25.07, 104.2% above the current price, from 2 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 2 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 5 analystsAvg $25.07
Low
$19.45
Now
$12.28
High
$31.78

MESO earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 43.4% on average.

  1. Q1 FY22: reported -$0.0332 per share against an estimate of -$0.0287
  2. Q2 FY22: reported -$0.0379 per share against an estimate of -$0.0479
  3. Q3 FY22: reported -$0.0313 per share against an estimate of -$0.0383
  4. Q4 FY22: reported -$0.0313 per share against an estimate of -$0.0479
  5. Q1 FY23: reported -$0.0227 per share against an estimate of -$0.0479
  6. Q2 FY23: reported -$0.0313 per share against an estimate of -$0.0603
  7. Q3 FY23: reported -$0.0237 per share against an estimate of -$0.0479
  8. Q4 FY23: reported -$0.0266 per share against an estimate of -$0.1252

MESO news

  • Vandana Singh

    Mesoblast Targets $10 Billion Market With Regenerative Back Pain Treatment

  • 9 Health Care Stocks Whale Activity In Today’s Session

  • 10 Health Care Stocks With Whale Alerts In Today’s Session

  • Press releasePRNewswire

    Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing It

  • Press releaseGlobe Newswire

    The $45 Billion Cell Therapy Boom Just Hit a Manufacturing Milestone Most Investors Haven't Noticed

  • Press releasePRNewswire

    A Key "Master" Protein That Declines by Half After Age 40. One Company Found a Way to Restore It.

  • Press releasePRNewswire

    Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them

  • What's Next: Mesoblast's Earnings Preview

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.